Q.AkkG.HuguenardJ
5 6 7 8 Recent narrative and scoping reviews specifically note the near-absence of human efficacy data and, for BPC-157, a reliance on a limited number of research groups
Gastrointestinal Adverse Reactions In the pool of placebo-controlled trials, gastrointestinal adverse reactions occurred more frequently among patients who received semaglutide tablets than placebo: semaglutide tablets 14 mg once daily (41%), semaglutide tablets 7 mg once daily (32%) and placebo (21%), including severe reactions (semaglutide tablets 14 mg 2.0%, semaglutide tablets 7 mg 0.6%, placebo 0.3%)
McPherson K, Vessey M, Neil A, Doll R, Jones L, Roberts M
For a person weighing 150 pounds (roughly 68 kg), this would mean a daily intake of 1,360 mg to 2,720 mg